School of Pharmaceutical Sciences, Shandong University, Jinan, China.
PLoS One. 2011;6(6):e20965. doi: 10.1371/journal.pone.0020965. Epub 2011 Jun 6.
Multidrug resistance (MDR) caused by overexpression of p-glycoprotein is a major obstacle in chemotherapy of malignant cancer, which usually is characterized by constitutive activation of signal transducer and activator of transcription 3 (STAT3), but their relation between MDR and STAT3 remains unclear. Here, we showed that STAT3 was overexpressed and highly activated in adriamycin-resistant K562/A02 cells compared with its parental K562 cells. Blockade of activation of STAT3 by STAT3 decoy oligodeoxynucleotide (ODN) promoted the accumulation and increased their sensitivity to adriamycin by down-regulating transcription of mdr1 and expression of P-gp, which were further confirmed by using STAT3-specific inhibitor JSI-124. Inhibition of STAT3 could also decrease mdr1 promoter mediated luciferase expression by using mdr1 promoter luciferase reporter construct. Otherwise, activation of STAT3 by STAT3C improved mdr1 transcription and P-gp expression. The ChIP results demonstrated that STAT3 could bind to the potential promoter region of mdr1, and STAT3 decoy depressed the binding. Further mutation assay show +64∼+72 region could be the STAT3 binding site. Our data demonstrate a role of STAT3 in regulation of mdr1 gene expression in myeloid leukemia and suggest that STAT3 may be a promising therapeutic target for overcoming MDR resistance in myeloid leukemia.
多药耐药(MDR)是恶性肿瘤化疗的主要障碍之一,这通常是由于 P-糖蛋白的过度表达引起的。P-糖蛋白是一种信号转导子和转录激活子 3(STAT3)的组成性激活所导致的。然而,它们之间的关系仍不清楚。在这里,我们发现与亲本 K562 细胞相比,阿霉素耐药 K562/A02 细胞中 STAT3 过度表达且高度激活。通过 STAT3 诱饵寡脱氧核苷酸(ODN)阻断 STAT3 的激活,通过下调 mdr1 和 P-糖蛋白的转录,促进了阿霉素的积累,并增加了其敏感性,这一点通过使用 STAT3 特异性抑制剂 JSI-124 进一步得到了证实。抑制 STAT3 还可以通过 mdr1 启动子荧光素酶报告载体抑制 mdr1 启动子介导的荧光素酶表达。相反,通过 STAT3C 激活 STAT3 可以改善 mdr1 转录和 P-糖蛋白的表达。ChIP 结果表明,STAT3 可以结合 mdr1 潜在启动子区域,而 STAT3 诱饵则抑制了结合。进一步的突变分析表明,+64∼+72 区域可能是 STAT3 的结合位点。我们的数据表明 STAT3 在调节髓系白血病中 mdr1 基因表达方面发挥作用,并表明 STAT3 可能是克服髓系白血病 MDR 耐药性的有前途的治疗靶点。